Hepatitis C

Researchers address the controversial topic of B-cell infection by hepatitis C.

A new test shows how well patients with hepatitis B respond to drugs.

Glecaprevir/pibrentasvir had a 99% SVR rate in a Japanese population.

The US Department of Veteran Affairs is finding success with modern DAAs.

3D treatment helped patients to attain SVR in less than 12 weeks.

Even after eradicating hepatitis C with direct-acting antivirals, high frequency of Tregs could pose complications.

Merck just got $2.54 billion richer with the ruling of a federal jury.

A trip to the beauty salon could result in exposure to dangerous blood-borne viruses.

An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.

Elbasvir/grazoprevir (Zepatier) and sofosbuvir (Sovaldi) are used to treat hepatitis C around the world, but is one better than the other?

“Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general population,” Scottish researchers found.

Increasing the duration of sofosbuvir/ribavirin treatment can cure more patients with hepatitis C genotype 2 with cirrhosis.

Gilead Sciences is seeking approval of a single tablet, 12-week combination hepatitis C regimen for patients of all genotypes previously treated for the disease with direct-acting antivirals.

The few hepatitis C rapid tests available now are either too expensive or lack quality – posing problems for extensive distribution.

Prisoners who are able to get hepatitis C antivirals while they are still incarcerated can be lost to treatment when they are freed. A community linkage program in the Bronx, NY is having success keeping the patients on their drug regimens.

When patients with chronic kidney disease also have untreated hepatitis C, the prognosis is grim. The combination can lead to end-stage renal disease, a study found.

Some of the different hepatitis C genotypes are more prominent in certain areas than others, and researchers specified where they're found around the world in people who inject drugs.

After a newspaper report found that less than 10 of Tennessee's thousands of HCV-positive prisoners were receiving treatment, two inmates sued the state. Now, prison officials are seeking a bit more help in battling the disease.

An investigational combination drug that targets all major genotypes of hepatitis C had a high success rate in a clinical trial of patients with severe chronic kidney disease, curing 98% of those who received 12 weeks of treatment.

Results from three clinical trials of an investigational drug being developed by AbbVie to treat all major genotypes of the hepatitis C virus show high cure rates at or above 95% among patients tested.

Sofosbuvir-based therapy is safe to treat patients with hepatitis C virus (HCV) who also have mental health disease.

A combination of tenofovir and alafenamide got FDA approval for treatment of hepatitis B viral infection with compensated liver disease.

Even in high-income countries, patients can have problems getting the expensive direct acting antivirals that are so effective in treating hepatitis C.

A project to wipe out hepatitis C among the Cherokee Nation to has led to successful screening of thousands of people since the effort was launched a year ago, say tribal leaders.

A combination of sofosbuvir, velpatasvir, and voxilaprevir was found highly effective for multiple HCV genotypes after short courses of treatment.

Some people favor coffee while others turn to energy drinks for their daily boost. But with all of that caffeine and sugar, it’s no wonder that the latter often gets a bad rep.

Researchers from the University of Georgia have created a mathematical model in hopes of finding the point at which infectious diseases like Zika explode from an isolated murmur into an outbreak roar.

Some women have an immunity boost against hepatitis C after giving birth, and two gene variants appear to be the reason why.

New hepatitis C treatments made accessible through competition and other access strategies have been given to over one million patients in as many as 13 low-and middle-income countries, according to a new report from the World Health Organization (WHO).

Noninvasive technology can accurately measure liver stiffness and track progress in liver disease cure.